Marksans Pharma shines as its arm receives marketing authorization from UK MHRA
Marksans Pharma is currently trading at Rs. 183.30, up by 5.00 points or 2.80% from its previous closing of Rs. 178.30 on the BSE.
The scrip opened at Rs. 180.45 and has touched a high and low of Rs. 184.55 and Rs. 180.30 respectively. So far 60409 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 358.50 on 02-Dec-2024 and a 52 week low of Rs. 168.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 215.35 and Rs. 177.00 respectively. The current market cap of the company is Rs. 8306.49 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 25.38% and 30.75% respectively.
Marksans Pharma’s wholly owned subsidiary in UK -- Relonchem has received marketing authorization for Metformin Hydrochloride Relonchem 500 mg, 750 mg and 1000 mg Prolonged Release Tablets from UK Medicines & Healthcare products Regulatory Agency (UK MHRA).
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
